NCT01407874View on ClinicalTrials.gov

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
GoutHyperuricemiaArthritisJoint DiseaseRenal Insufficiency
Interventions
DRUG

Placebo

Oral dose administered daily for 84 days.

DRUG

Ulodesine (BCX4208) 5 mg

Oral dose administered daily for 84 days.

DRUG

Ulodesine (BCX4208) 10 mg

Oral dose administered daily for 84 days.

Trial Locations (10)

22304

Alexandria

34677

Oldsmar

36608

Mobile

37923

Knoxville

67114

Newton

75235

Dallas

78215

San Antonio

85381

Peoria

92618

Irvine

96814

Honolulu

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY